Tunable Polymeric Nanoparticles for Antibiotic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering glycopeptide antibiotics, such as vancomycin, to treat bacterial infections, particularly biofilm infections, result in systemic toxicities due to the need for high doses and frequent administration, which fail to maintain a sustained and high local concentration of the antibiotics.
Innovation Solution
Development of copolymers and glycopeptide antibiotic-loaded polymeric nanoparticles (PNPs) with a tunable negative charge density-to-hydrophobicity ratio, allowing for efficient loading and encapsulation of positively charged glycopeptide antibiotics, and optionally attaching a targeting moiety for enhanced delivery to infection sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses and frequent administration of glycopeptide antibiotics are used, then the local concentration of antibiotics is improved, but systemic toxicities worsen
Solution Approach 1:
The patent segments the antibiotic delivery system into nanoparticles with specific size ranges (50-200 nm) that can accumulate at infection sites through enhanced permeability and retention effect, allowing localized high concentration without proportional systemic exposure. The copolymer structure is also segmented into hydrophilic PEG blocks and hydrophobic antibiotic-loading blocks, enabling selective drug release at the target site.
Solution Approach 2:
The patent introduces copolymer nanoparticles as an intermediary carrier between the systemic circulation and the infection site. These nanoparticles protect the antibiotic during circulation, enable targeted accumulation at biofilm sites, and provide controlled release, thereby achieving high local concentration while minimizing direct systemic toxicity through the mediating nanoparticle system.
2Reliability
If frequent administration of high doses is used, then the treatment effectiveness is improved, but the treatment duration and patient burden worsen
Solution Approach 1:
The patent achieves continuous antibiotic action through sustained release from the nanoparticle carrier. The copolymer matrix provides gradual release of the antibiotic over extended periods, maintaining therapeutic levels continuously rather than requiring repeated dosing. This continuous action improves treatment effectiveness while reducing the frequency and duration of treatment protocols.
Solution Approach 2:
The patent changes the release rate parameter of the antibiotic by controlling nanoparticle composition, size, and structure. By adjusting the copolymer ratio, nanoparticle size, and loading method, the release kinetics are optimized to maintain sustained therapeutic levels, extending the effective action duration and reducing administration frequency.
3Ease of operation
If conventional administration methods are used, then the simplicity of administration is maintained, but the ability to maintain sustained high local concentration worsens
Solution Approach 1:
The patent creates a universal nanoparticle platform that combines multiple functions: circulation stability via PEGylation, antibiotic loading through hydrophobic interactions, targeted accumulation at infection sites, and sustained release capabilities. This multi-functional nanoparticle system maintains ease of intravenous administration while achieving sustained local concentration that conventional methods cannot provide.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these nanoparticles achieves targeted and sustained delivery of glycopeptide antibiotics, reducing systemic exposure and toxicity while maintaining high local concentrations, effectively treating bacterial infections including biofilm infections.
Implementation Method 1
the copolymers of the PNPs can be customized to efficiently load and encapsulate positively charged glycopeptide antibiotics
Implementation Method 2
tunable negative charge density-to-hydrophobicity ratio
Data Source
AI summary
The present disclosure provides copolymers and glycopeptide antibiotic-loaded polymeric nanoparticles (PNPs) comprising the copolymers as well as charge neutral polymers for targeted and sustained delivery of glycopeptide antibiotics to treat bacterial infections, including but not limited to biofilm bacterial infections. The copolymers are block, alternate, or random copolymers comprising x units of the formulaand y units of the formulawherein Z is an organic moiety, R and R′ are each independently selected from the group consisting of hydrogen and C1-C18 alkyl, each of x and y is an integer of 1 or greater, the sum of x and y is an integer from about 40 to about 714, and y is from about 10% to about 90% of the sum of x and y.